FDA expands approval of BioCryst's rare disease drug for use in young children

BioCryst Pharmaceuticals

12/12/2025 12:05

Dec 12 (Reuters) - The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' BCRX.O drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to under 12 years, the company said on Friday.

 (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber)

 ((siddhi.mahatole@thomsonreuters.com;))